title: Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro.
abstract: BACKGROUND
  Imexon, a 2-cyanoaziridine, is therapeutic and reverses lymphadenopathy and splenomegaly in the LP-BM5 murine retrovirus-induced immunodeficiency disease (murine AIDS). It can restore chemotherapy-induced immunosuppression. Imexon reduced the incidence of lymphoma in severe combined immune deficient mice inoculated with human lymphocytes.
  
  
  OBJECTIVE
  To determine its antitumor activity, we screened imexon against fresh human tumor cells and tumor cell lines. To determine the time-concentration relationships of its cytotoxicity, we studied the effects of imexon on macromolecular synthesis and on the cell cycle.
  
  
  METHODS
  Imexon was incubated at 1-200 micrograms/mL with various tumor cell lines, mitogen-stimulated peripheral blood lymphocytes, and fresh tumor cells. Cell survival, macromolecular synthesis, and cell cycle progression were studied.
  
  
  RESULTS
  The concentration of imexon that caused 50% inhibition of growth was under 10 micrograms/mL for lymphocytes stimulated with mitogens. It was about 3-10 micrograms/mL for B-cell lymphomas and both multi-drug-resistant and -sensitive myeloma cell lines. Imexon inhibited four of seven fresh lymphoma and 11 of 16 fresh myeloma biopsy specimens to less than 40% of the control. A 1-hour exposure of lymphoma cells to 50-100 microgram/mL followed by removal of drug by washing the cells and continuing culture resulted in greater than 95% inhibition during the next 48-72 hours. Imexon selectively inhibited protein synthesis during the first 24-48 hours of exposure of lymphoma and myeloma cells. Cells exposed to inhibitory concentrations of imexon were blocked in cell cycle progression.
  
  
  CONCLUSIONS
  Imexon may be a potentially useful agent in the treatment of malignant disease, particularly lymphoid malignancies, and should be explored further.
authors.affiliation: Section of Hematology and Oncology, Arizona Cancer Center, Tucson 85724.
authors.forename: E M
authors.initials: EM
authors.lastname: Hersh
authors.forename: C R
authors.initials: CR
authors.lastname: Gschwind
authors.forename: C W
authors.initials: CW
authors.lastname: Taylor
authors.forename: R T
authors.initials: RT
authors.lastname: Dorr
authors.forename: R
authors.initials: R
authors.lastname: Taetle
authors.forename: S E
authors.initials: SE
authors.lastname: Salmon
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006588:Hexanones / Q000494:pharmacology*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D006588:Hexanones; C014919:4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one